These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31338476)

  • 1. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
    Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
    Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
    Ruthirakuhan M; Herrmann N; Andreazza AC; Verhoeff NPLG; Gallagher D; Black SE; Kiss A; Lanctôt KL
    J Alzheimers Dis; 2019; 71(1):21-31. PubMed ID: 31322567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
    Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
    PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agitation and aggression in people living with dementia and mild cognitive impairment in shared-housing arrangements - validation of a German version of the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF).
    Kratzer A; Scheel-Barteit J; Altona J; Wolf-Ostermann K; Graessel E; Donath C
    Health Qual Life Outcomes; 2023 May; 21(1):51. PubMed ID: 37248478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
    De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
    J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
    Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial.
    Ballard C; Corbett A; Orrell M; Williams G; Moniz-Cook E; Romeo R; Woods B; Garrod L; Testad I; Woodward-Carlton B; Wenborn J; Knapp M; Fossey J
    PLoS Med; 2018 Feb; 15(2):e1002500. PubMed ID: 29408901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD).
    Cohen LM; Ash E; Outen JD; Vandrey R; Amjad H; Agronin M; Burhanullah MH; Walsh P; Wilkins JM; Leoutsakos JM; Nowrangi MA; Harper D; Rosenberg PB; Forester BP
    Int Psychogeriatr; 2021 Oct; ():1-6. PubMed ID: 34629131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
    Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
    CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.